Safety and immunogenicity of AGS-v PLUS, a mosquito saliva peptide vaccine against arboviral diseases: A randomized, double-blind, placebo-controlled Phase 1 trialResearch in context

Safety and immunogenicity of AGS-v PLUS, a mosquito saliva peptide vaccine against arboviral diseases: A randomized, double-blind, placebo-controlled Phase 1 trialResearch in context

Summary: Background: Immunity to mosquito salivary proteins could provide protection against multiple mosquito-borne diseases and significantly impact public health. We evaluated the safety and immunogenicity of AGS-v PLUS, a mosquito salivary peptide vaccine, in healthy adults 18–50 years old. Met...

Full description

Bibliographic Details
Main Authors: DeAnna J. Friedman-Klabanoff, Megan Birkhold, Mara T. Short, Timothy R. Wilson, Claudio R. Meneses, Joshua R. Lacsina, Fabiano Oliveira, Shaden Kamhawi, Jesus G. Valenzuela, Sally Hunsberger, Allyson Mateja, Gregory Stoloff, Olga Pleguezuelos, Matthew J. Memoli, Matthew B. Laurens
Format: Article
Language:English
Published: Elsevier 2022-12-01
Series:EBioMedicine
Subjects:
Mosquito-borne diseases
Vector-borne viruses
Mosquito-borne disease vaccine
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396422005576

Internet

http://www.sciencedirect.com/science/article/pii/S2352396422005576

Similar Items